Scientific Programme of the CELCC 2020
(as of November 18, 2020. The programme is continuously updated)
Friday, November 27
Opening sessionChairs:
Luboš Petruželka, Czech Republic
Robert Pirker, Austria
Gyula Ostoros, Hungary
|
12:30 – 12:35 | Opening remarks | Luboš Petruželka, Czech Republic |
| 12:35 – 13:00 | Statistics in clinical trials and medical research | Ondřej Májek, Czech Republic | |
| 13:00 – 13:10 | Discussion | ||
|
Session I: Early detection in clinical practice & research
Chairs:
Gyula Ostoros, Hungary
Jiří Votruba, Czech Republic
|
13:10 – 13:30 | Management of small lung nodules | Helmut Prosch, Austria |
| 13:30 – 13:50 | Circulating biomarkers in early detection and treatment of lung cancer – sponsored by Sotio | Filip Janků, USA | |
| 13:50 – 14:10 |
Pilot screening project in the Czech Republic – sponsored by AstraZeneca |
Jiří Votruba, Czech Republic | |
| 14:10 – 14:30 | Experience with screening in Croatia | Ante Marušić, Croatia | |
| 14:30 – 14:50 | HUNCHEST screening in Hungary | Anna Kerpel-Fronius, Hungary | |
| 14:50 – 15:10 | Panel discussion | ||
| Break | 15:10 – 15:40 | ||
| Satellite symposium I | 15:40 – 16:40 |
ROCHE |
|
| Break | 16:40 – 16:50 | ||
|
Session II: Precision diagnosis of lung cancer Chairs:
David Zogala, Czech Republic |
16:50 – 17:15 | Artificial intelligence in imaging | Lukáš Lambert, Czech Republic |
| 17:15 – 17:40 | New technologies in imaging | David Zogala, Czech Republic | |
| 17:40 – 18:05 | Next generation sequencing in diagnosis: indications and utilization rate | Jószef Tímár, Hungary | |
| 18:05 – 18:30 |
Predictive biomarkers for the treatment of NSCLC |
Kristýna Němejcová, Czech Republic | |
| approx. 5 minutes of Q & A section is a part of each lecture in this session | |||
|
Special session:
Petr Zatloukal Memorial lecture |
18:30 – 19:00 | Conquering lung cancer in Central Europe | Jean Klastersky, Belgium |
Saturday, November 28
Session III: Therapy of early stage lung cancer Chairs: Stanislav Trča, Czech Republic Renata Soumarová, Czech Republic
| 8:30 – 8:55 | Minimally invasive surgery | Mir Alireza Hoda, Austria |
| 8:55 – 9:20 | Proton radiotherapy in early stage of lung cancer treatment | Jiří Kubeš, Czech Republic | |
| 9:20 – 9:45 | Stereotactic radiotherapy of NSCLC | Jakub Cvek, Czech Republic | |
| 9:45 – 10:10 | The role of radiotherapy fractionation | Karin Dieckmann, Austria | |
| approx. 5 minutes of Q & A section is a part of each lecture in this session | |||
| Break | 10:10 – 10:40 | ||
Session IV: Trimodality therapy of locally advanced NSCLC – current status and perspectives Chairs: Milada Zemanová, Czech Republic sponsored by AstraZeneca | 10:40 – 11:00 | Care of patients with Non-Small-Cell lung cancer stage III – the Central European real-world experience – final analysis – sponsored by AstraZeneca | Milada Zemanová, Czech Republic |
| 11:00 – 11:20 | Patient case study: tratment variability in N2 positive stage III NSCLC | Daniel Krejčí, Czech Republic | |
| 11:20 – 11:40 | Adjuvant therapy of resected NSCLC | Robert Pirker, Austria | |
| 11:40 – 12:00 | Induction therapy followed by surgery in NSCLC | Renata Soumarová, Czech Republic | |
| 12:00 – 12:20 | Definitive chemoradiotherapy | Jacek Jassem, Poland | |
| 12:20 – 12:40 | Panel discussion | ||
| Break | 12:40-13:10 | ||
| Satellite symposium II. | 13:10 – 14:10 | Bristol-Myers Squibb | |
| Break | 14:10 – 14:20 | ||
Session V: Immunotherapy of metastatic lung cancer – current evidence Chairs: Luboš Petruželka, Czech Republic Leona Koubková, Czech Republic sponsored by MSD | 14:20 – 14:40 | Immunotherapy beyond checkpoint inhibitors | Radek Špíšek, Czech Republic |
| 14:40 – 15:00 | Atezolizumab in metastatic lung cancer – current evidence | Libor Havel, Czech Republic | |
| 15:00 – 15:20 | Durvalumab (metastatic non small cell lung cancer) | Gyula Ostoros, Hungary | |
| 15:20 – 15:40 | Nivolumab | Helena Linardou, Greece | |
| 15:40 – 16:00 | Pembrolizumab | Luboš Petruželka, Czech Republic | |
| 16:00 – 16:20 | Panel discussion | ||
| Break | 16:20 – 16:50 | ||
Session VI: Targeted therapies of mutation-positive NSCLC Chairs: Jana Skřičková, Czech Republic Miloš Pešek, Czech Republic | 16:50 – 17:15 | EGFR mutation-positive NSCLC: recent advances | Krisztina Bogos, Hungary |
| 17:15 – 17:40 | ALK-positive NSCLC: recent advances | Peter Beržinec, Slovakia | |
| 17:40 – 18:05 | Liquid biopsy for disease monitoring | Martin Filipits, Austria | |
| 18:05 – 18:30 | Novel targets and drugs | Nir Peled, Israel | |
| approx. 5 minutes of Q & A section is a part of each lecture in this session | |||
Sunday, November 29
12:20 – 12:30Poster presentation 4TBA
| Board: radiologist Andrea Burgetová, General Univ. Hospital, pathologist Radoslav Matěj, Thomayer Hospital, medical oncologists Milada Zemanová and Luboš Petruželka, General Univ. Hospital, radiation oncologists Soňa Argalácsová, General Univ. Hospital, surgeon Jan Kolařík, Univ. Hospital Motol, pneumologist Helena Čoupková, Masaryk Memorial Cancer Institute | |||
Session VII: Multidisciplinary tumor board – locally advanced / metastatic NSCLC, 3 cases Chairs: Robert Pirker, Austria Martin Svatoň, Czech Republic | 9:00 – 9:30 | Agressive pulmonary adenocarcinoma with new FGFR translocation and cMET mutation not responsive to crizotinib and nintedanib treatment – a case report | Martin Svatoň, Czech Republic |
| 9:30 – 10:00 | Multidisciplinary management in stage III NSCLC | Thomas Klikovits, Austria | |
| 10:00 – 10:30 | Successful multivariate treatment of stage IV EGFR Exon-19 mutant pulmonary adenocarcinoma | Gabriella Gálffy, Hungary | |
| Break | 10:30 – 11:00 | ||
Session VIII: SCLC, Mesothelioma and best posters presentation
Chairs: Nevena Secen, Serbia Helena Čoupková, Czech Republic | 11:00 – 11:25 | Small cell lung cancer: treatment advances | Nevena Secen, Serbia |
| 11:25 – 11:50 | Malignant pleural mesothelioma: treatment advances | Marko Jakopović, Croatia | |
| 11:50 – 12:00 | Poster presentation – Definitive chemoradiotherapy of locally advanced Non-Small Cell Lung Cancer (LA-NSCLC) with IGRT technique using tomotherapy HD – updated asnalysis | Stanislav Hloušek et all., Czech Republic | |
| 12:00 – 12:10 | Poster presentation – The role of serum tumour markers in the detection of malignant lung tumours | Martin Skála et all., Czech Republic | |
| 12:10 – 12:20 | Poster presentation – Impact of concomitant medication administered at the time of initiation of the outcome of nivolumab therapy in Non-Small Cell Lung Cancer | Martin Svatoň et all., Czech Republic | |
| 12:20 – 12:30 | Poster presentation – Examination of the immune cells profile of NSCLC patients indicated for inhibitory checkpoint immunotherapy | Jan Špaček et all., Czech Republic | |
| approx. 5 minutes of Q & A section is a part of each lecture in this session | |||
Closing Remarks | 12:30 – 13:00 | ||
